M&A Deal Summary |
|
|---|---|
| Date | 2017-12-23 |
| Target | Discuva |
| Sector | Life Science |
| Buyer(s) | Summit Therapeutics |
| Deal Type | Add-on Acquisition |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 2003 |
| Sector | Life Science |
| Employees | 159 |
| Revenue | 1M USD (2022) |
Summit Therapeutics is a biopharmaceutical company focused on the discovery and development of novel medicines to treat the fatal muscle wasting disease Duchenne muscular dystrophy and infections caused by the bacteria C. difficile. Summit Therapeutics was founded in 2003 and is based in Miami, Florida.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Add-on Acquisition M&A Deals | 1 of 1 |
| Country: United Kingdom M&A | 1 of 1 |
| Year: 2017 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2009-09-02 |
Dextra Laboratories
Reading, United Kingdom Dextra Laboratories Ltd. is involved in developing innovative solutions to minimise costs, reduce technology transfer issues and optimise robust route generation. The company supplies rare sugars, oligosaccharides and chiral molecules for medical research, diagnostics and pharmaceutical applications. |
Sell | - |
